10.25376/hra.7845242.v1
Jason Stubbs
Jason
Stubbs
Margaret Stedman
Margaret
Stedman
Sai Liu
Sai
Liu
Jin Long
Jin
Long
Yoko Franchetti
Yoko
Franchetti
Raymond West III
Raymond
West III
Alex Prokopienko
Alex
Prokopienko
Jonathan Mahnken
Jonathan
Mahnken
Glenn Chertow
Glenn
Chertow
Tom Nolin
Tom
Nolin
Stubbs et al - TMAO and CV Outcomes in EVOLVE_CJASN.pdf
Health Research Alliance
2019
cardiovascular disease
chronic kidney disease
gut microbiome
end-stage kidney disease
Cardiology (incl. Cardiovascular Diseases)
Nephrology and Urology
2019-03-14 17:33:56
Journal contribution
https://hra.figshare.com/articles/journal_contribution/Stubbs_et_al_-_TMAO_and_CV_Outcomes_in_EVOLVE_CJASN_pdf/7845242
The data demonstrates that baseline levels of TMAO, a circulating compound derived from byproducts of intestinal bacteria, do not predict cardiovascular endpoints in patients with end-stage kidney disease.